RA'ANANA, Israel, Nov. 29,
2023 /PRNewswire/ -- Inspira Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the
"Company" or "Inspira"), an innovator in life support technology,
is excited to announce a partnership with Ennocure MedTech Ltd.
At the core of Inspira's mission is a groundbreaking approach to
oxygenate blood directly to replace life support mechanical
ventilation. Inspira seeks to include bio-electronic technology as
part of the INSPIRA ART and Company's IP portfolio, to prevent the
growth of bacteria that often results in a bloodstream infection
(sepsis) and has partnered with Ennocure for the development of
such treatment.
Today, it is estimated that 250,000 bloodstream infections
related to intravenous lines occur worldwide each year, leading to
prolonged hospital stays and increasing healthcare costs.
Once developed, Inspira plans to combine the bio-electronic
novel physical stimulation technology, as a preemptive measure for
potentially at-risk patients, providing a cost-competitive solution
to reduce complications.
Dagi-Ben Noon, CEO of Inspira, reflects on the partnership's
significance: "By Integrating our technology to oxygenate blood
directly with Ennocure's infection prevention solutions, we are
focusing on potentially improving patient outcomes in ICUs and
paving the way for safer, more effective life-support treatments.
This collaboration is expected to accelerate the development and
broaden the implementation of our advanced technology."
About Ennocure MedTech Ltd.
Ennocure, is a pioneer in the development of bio-electronic
Wound Dressing. At the core of the technology is a proprietary
bio-electronic wound dressing designed to prevent bacterial
infections, while providing remote wound monitoring & infection
alerts based on AI-driven personalized therapy.
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is leading the way in transforming
life-support care. Its innovative solutions are paving the way for
direct blood oxygenation, bypassing the lungs, and potentially
reducing the need for traditional mechanical ventilation. Beyond
this, the Company is committed to advancing blood circulation
technology and incorporating AI-driven monitoring systems. These
advancements are part of its strategy to offer more
patient-focused, data-informed care. The integration of these
technologies signifies the potential to enhance patient outcomes
and streamline hospital operations, marking a new era in
respiratory care.
For more information, please visit our corporate website:
https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the partnership with
Ennocure MedTech Ltd for the development of a bio-electronic
treatment to prevent Associated Bloodstream Infections in ICU
Patients, when it discusses the benefits of the treatment and
the integration of Ennocure's technology, when it discusses
Inspira's plans to combine the bio-electronic novel physical
stimulation technology, as a preemptive measure for potentially
at-risk patients, providing a cost-competitive solution to reduce
complications, or when it discusses that this collaboration is
expected to accelerate the development and broaden the
implementation of Inspira's technology . Except as otherwise
required by law, the Company undertakes no obligation to publicly
release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting the Company is
contained under the heading "Risk Factors" in the Company's annual
report on Form 20-F for the fiscal year ended December 31, 2022 filed with the SEC, which is
available on the SEC's website, www.sec.gov.
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2023 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-collaborates-with-ennocure-for-development-of-a-proprietary-bio-electronic-treatment-to-prevent-associated-bloodstream-infections-in-icu-patients-302000779.html
SOURCE Inspira Technologies